Product Description
CMND-100 is being developed by Clearmind Medicine for the treatment of alochol use disorder. (Sourced from: https://www.clearmindmedicine.com/news-release/clearmind-announces-successful-pre-ind-meeting-with-u-s-fda-for-cmnd-100-for-alcohol-use-disorder)
Mechanisms of Action: 5-HT2A Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Clearmind Medicine
Company Location: Eastern America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Israel, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Expected - Clearmind Medicine announced they will present P1 Alcoholism results on 2026-06-10 for CMND-100
- Clinical Outcomes Reported - Clearmind Medicine presented P1 Alcoholism results on 2026-04-20 for CMND-100
- Clinical Outcomes Reported - Clearmind Medicine presented P1 Alcoholism results on 2026-04-14 for CMND-100
Highest Development Phases
Phase 2: Alcoholism
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05913752 |
CM-CMND-001 | P2 |
Recruiting |
Alcoholism |
2026-12-31 |
12% |
2026-04-01 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |